Selective TSP-1/CD47 antagonization as a new anti-thrombotic opportunity – THROMBOTAX

Thrombospondin 1 (TSP1), a major protein from platelet alpha granules being overexpressed in cardiovascular diseases, plays a key role in haemostasis and thrombosis. TSP1 interaction with CD47 enhances platelet adhesion as well as aggregation while stabilizing platelet aggregates. Thus, targeting the TSP1/CD47 axis is pharmacologically relevant for controlling platelet activation in thrombotic cardiovascular diseases. We previously engineered TAX2 peptide as the first ever selective antagonist for TSP1/CD47 axis. Data from our lab indicate that TAX2 treatment inhibits platelet aggregation in vitro and displays antithrombotic properties in mice, without increasing bleeding risk. This project, which main objective is to validate TAX2 drug candidate as a therapeutic option for thrombotic disorders, is based on a highly complementary consortium between academic teams and a biotechnology company developing peptide-based therapeutic strategies.